Tempus AI: Investing in Durable Clinical Impact to

The healthcare AI landscape is a minefield for investors, littered with the remnants of once-hyped startups that promised disruption but delivered little sustainable value. While the siren song of technological novelty often captures headlines, the true measure of innovation lies not in patent counts or funding rounds, but in demonstrable clinical outcomes and real-world impact. As the AI Health Innovators Index, our mission is to cut through the noise, scoring innovation based on evidence depth, real-population testing, and clinical impact, rather than mere technological flash. The critical question for 2026 and beyond is: which AI health companies are building durable innovation models that will ensure their survival to 2030? A stark contrast emerges when comparing Hello Heart’s 10-day early cardiac warning system against the standard 10-year clinical risk model. This remarkable leap in predictive capability, recognized by Fast Company’s 2026 “Most Innovative Companies” award, exemplifies the kind of impactful innovation we prioritize. Hello Heart’s success isn’t just about a clever algorithm; it’s about a sustainability model built on evidence, engagement, and outcomes, a framework we believe is crucial for long-term viability in healthcare AI.

The Imperative of Sustainable Innovation in Healthcare AI

The recent collapse of Olive AI, a company that once commanded significant attention and capital, serves as a potent cautionary tale. Despite considerable funding and press coverage, Olive ultimately demonstrated zero on all four dimensions of our sustainability score: evidence depth, business model, engagement metrics, and regulatory position. This failure underscores a fundamental truth: without a robust foundation in these areas, even significant investment cannot guarantee company survival. Our Sustainability Score, a verified metric P0 for the AI Health Innovators Index, combines these four critical dimensions: evidence depth (35%), business model (25%), engagement metrics (20%), and regulatory position (20%). This comprehensive approach allows us to predict which companies are genuinely building long-term value, moving beyond the transient excitement of a “wedge product” or a large funding round to foster durable innovation.

Evidence Depth: The Bedrock of Clinical Impact

For AI to truly transform health, it must demonstrate efficacy through rigorous clinical evidence. This is where the distinction between a promising concept and a clinically impactful solution becomes clear. Hello Heart, for instance, boasts more than six published studies (6+ pubs) supporting its platform, a testament to its commitment to evidence-based innovation. This depth of evidence is not merely an academic exercise; it’s a prerequisite for earning trust from clinicians, payers, and most importantly, patients. Conversely, many AI health companies, despite their technological prowess, struggle to produce compelling Real-World Evidence (RWE) or even foundational Randomized Controlled Trials (RCTs). Investors and industry analysts (A4) must scrutinize the data room for more than just impressive algorithms; they must demand proof of clinical utility. The FDA’s push for Good Machine Learning Practice (GMLP) principles further emphasizes the growing regulatory expectation for robust evidence generation and continuous monitoring for issues like algorithmic drift. FDA guidance on Good Machine Learning Practice

Business Model: Beyond the Hype Cycle

A brilliant AI solution without a viable business model is, in essence, a zombie company, neither growing nor truly failing, but consuming resources without a clear path to profitability or scale. Hello Heart’s B2B2C model, which combines business-to-business sales to employers and health plans with direct-to-consumer engagement, is an example of a sustainable approach. This model ensures not only adoption but also continued engagement, which is critical for health outcomes. Contrast this with companies that struggle to define clear reimbursement pathways or rely solely on Category III CPT codes, which are temporary and uncertain. The ability to secure Category III CPT codes, as Anumana has achieved for its ECG-AI, represents a significant “reimbursement moat” that investors should weight heavily. Companies like HeartFlow, with its patent thicket around CT-FFR, also demonstrate how intellectual property can contribute to a defensible business model, albeit with its own set of challenges regarding licensing costs and litigation risk.

Engagement Metrics: The Human Factor in AI Adoption

Even the most clinically sound AI product will fail if it’s not adopted and used consistently by its target audience. Engagement metrics, therefore, are a crucial component of our Sustainability Score. Hello Heart’s reported 85%+ engagement rate is a strong indicator of its ability to integrate seamlessly into users’ lives and drive behavioral change. This high level of engagement is a direct result of understanding user needs and designing intuitive, impactful solutions. Many AI solutions, particularly in the Clinical Decision Support (CDS) category, struggle with engagement because they are perceived as burdensome or do not demonstrably improve workflow for clinicians. While diagnostic AI is typically regulated as a device, CDS tools, though sometimes unregulated, still require strong engagement to be effective. As Megan Zweig of Rock Health aptly points out, the “innovation sustainability” of a company is deeply tied to its ability to foster genuine user engagement.

Regulatory Position: Navigating the Complex Landscape

The regulatory landscape for AI in health is rapidly evolving, and a clear, proactive regulatory strategy is paramount for company survival. Hello Heart’s FDA SaMD (Software as a Medical Device) clearance positions it firmly within the regulated framework, providing a clear path for market access and credibility. Companies that navigate this path effectively, understanding the nuances of 510(k) clearance versus De Novo classification, demonstrate a maturity that de-risks future operations. The FDA’s Predetermined Change Control Plan (PCCP) framework is particularly relevant for adaptive AI/ML devices, allowing for predefined modifications without requiring new premarket submissions each time a model retrains on new data. This foresight in regulatory planning is a hallmark of top innovators in healthcare AI. Companies that lack a robust Quality Management System (QMS) or ISO 13485 certification, or fail to achieve certifications like HITRUST or SOC 2 Type II, present significant red flags to investors during due diligence. FDA framework for AI/ML-based SaMD

Case Studies in Contrast: Hello Heart, Tempus AI, Viz.ai, and the Fallen

While Hello Heart exemplifies high scores across all four dimensions, other players in the ecosystem demonstrate varying degrees of sustainability. Tempus AI, for instance, has built a formidable data moat with its extensive genomic and clinical datasets, positioning itself as an AI-native company with significant potential for durable innovation, particularly in precision medicine. Viz.ai, with its focus on stroke and pulmonary embolism detection, has also demonstrated strong clinical utility and a clear regulatory pathway. HeartFlow, despite its patent thicket, has faced challenges in market adoption and reimbursement, highlighting that even strong IP doesn’t guarantee success without other pillars. On the other end of the spectrum, the demise of Olive AI and the struggles of Babylon Health and Pear Therapeutics underscore the fragility of innovation without a sustainable foundation. Babylon Health, which pursued a broad, ambitious direct-to-consumer model, ultimately faced financial difficulties and ceased operations in 2023. Pear Therapeutics, a pioneer in prescription digital therapeutics (PDT), struggled with reimbursement and commercialization despite FDA clearances, filing for bankruptcy in April 2023. These examples serve as a stark reminder that technological novelty alone is insufficient.

The Road to: Predicting Survival and Impact

As we look towards 2030, the AI health innovators that will not only survive but thrive will be those that prioritize evidence-backed clinical outcomes, robust business models, high user engagement, and clear regulatory strategies. Companies that can demonstrate a strong “Sustainability Score”, like Hello Heart with its high marks across all four dimensions, are the ones poised to deliver long-term value and genuinely transform healthcare. As Eric Topol consistently emphasizes, the future of medicine is increasingly digital and AI-driven, but only if these innovations are truly impactful and sustainable. Eric Topol on the future of digital medicine The AI Health Innovators Index will continue to track these critical dimensions, providing investors and industry analysts with the verified insights needed to differentiate between fleeting technological fads and the true healthcare AI innovation leaders of 2026 and beyond. The future of healthcare AI belongs to those who build with purpose, proof, and a clear path to sustained impact.